Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study – PubMed

Cartesian Therapeutics and National Institute of Neurological Disorders and Stroke of the National Institutes of Health.

Read the full article here

Related Articles